---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-191566"
form_type: "8-K"
ticker: "MPLT"
cik: "0001770069"
company_name: "MapLight Therapeutics, Inc."
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T02:21:26.042765+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Two MapLight directors not standing for reelection; Babler and Cox nominated

## Summary
- Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D. will not stand for reelection at the June 23, 2026 Annual Meeting.
- Board nominated Martin Babler and Troy Cox as Class I director nominees to replace them.
- Both departures are not due to any disagreement with the Company on operations, policies, or practices.

## SEC filing metadata
- accession: 0001193125-26-191566
- form_type: 8-K
- ticker: MPLT
- cik: 0001770069
- company_name: MapLight Therapeutics, Inc.
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770069/000119312526191566/0001193125-26-191566-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770069/000119312526191566/d114505d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-191566
- JSON: https://secwatch.observer/filing/0001193125-26-191566.json
- Plain text: https://secwatch.observer/filing/0001193125-26-191566.txt

## Key facts
- Executive change
  Martin Babler was appointed as Class I Director at MapLight Therapeutics, Inc..
  - Action: nominated
  - Role: Class I Director
  source text: The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace Dr. Malenka and Dr. Trenkle.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770069/000119312526191566/0001193125-26-191566-index.htm
- Executive change
  Jim Trenkle departed as Director at MapLight Therapeutics, Inc..
  - Action: not stand for reelection
  - Role: Director
  source text: On April 23, 2026, Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors (the "Board") of MapLight Therapeutics, Inc. (the "Company") of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770069/000119312526191566/0001193125-26-191566-index.htm
- Executive change
  Troy Cox was appointed as Class I Director at MapLight Therapeutics, Inc..
  - Action: nominated
  - Role: Class I Director
  source text: The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace Dr. Malenka and Dr. Trenkle.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770069/000119312526191566/0001193125-26-191566-index.htm
- Executive change
  Robert Malenka departed as Director at MapLight Therapeutics, Inc..
  - Action: not stand for reelection
  - Role: Director
  source text: On April 23, 2026, Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors (the "Board") of MapLight Therapeutics, Inc. (the "Company") of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770069/000119312526191566/0001193125-26-191566-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.